---
document_datetime: 2023-09-21 22:03:21
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/atazanavir-krka-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: atazanavir-krka-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.3094342
conversion_datetime: 2025-12-28 01:22:25.818107
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Atazanavir Krka

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0003              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation       | 06/06/2023                          |                                             | SmPC and PL                      |           |
| IB/0002/G            | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a | 13/10/2021                          | 15/11/2021                                  | SmPC, Annex II and PL            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                        |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0001 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                 | 18/08/2021 | 15/11/2021 | SmPC, Labelling and PL |